|

fruquintinib＋trastuzumab + XELOX Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Henan Cancer Hospital1

Indications

  • GEJ Adenocarcinoma1
  • First Line Therapy1
  • HER2-positive Gastric Cancer1
  • Fruquintinib1
  • Gastric Adenocarcinoma1

Other1 trial

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.